AusBiotech has shared the latest release of Australasian Biotechnology during the biggest week in Australian medtech.
The publication shares insights into the research, policy, and commercialisation trends shaping Australia’s life sciences ecosystem, including submissions from members Adherium, Bellberry, CBE Pure Solutions, Endpoints Capital, Emball'iso, Orthocell, QBiotics Group, and Southern Clinical Development Consulting.
With expert editorial and sector-wide relevance, it is essential reading for anyone working to advance biotechnology, medical technology, and digital health.
The latest Australasian Biotechnology explores:
- AI’s role in transforming drug discovery and medtech innovation;
- Strengthening Australia’s local manufacturing and commercialisation capacity;
- Strategies to accelerate clinical trials and insights from Bellberry;
- Sustainability in pharmaceutical logistics and nature-based drug development;
- Sector highlights from AusBiotech Conference; and,
- Market trends from the latest AusBioStock Index.
Giving voice to the sector
“As Australia’s life sciences peak body, we’re proud to provide our members with a national platform to share their innovations, insights, and sector leadership,” said AusBiotech CEO Rebekah Cassidy.
“Providing this channel to showcase their contributions — from drug discovery and diagnostics to regulatory reform and sustainability — is something we will continue to champion.”
"Today, more than 2905 life sciences organisations operate in Australia – nearly double the 2017 figures,” continued Ms Cassidy. “Of these, 1592 are biotechnology and medical technology companies, including 691 in pharmaceuticals and biotech, and 901 in medtech. The sector now supports nearly 350,000 highly skilled jobs – approximately 1.7 per cent of the Australian workforce.
“These numbers demonstrate our industry’s critical role in contributing to the Australian economy, boosting productivity, and advancing health outcomes for Australians and patients worldwide”.
